Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge
08:57am, Tuesday, 30'th Dec 2025
Biogen Inc. shares, despite retail investor pessimism, rose 15.1% in 2025. Besides the successful launch of Leqembi, I highlight Skyclarys, an Nrf2 activator for the treatment of Friedreich's ataxia,
Assenagon Asset Management S.A. Cuts Stake in Biogen Inc. $BIIB
03:20am, Thursday, 25'th Dec 2025
Assenagon Asset Management S.A. cut its position in Biogen Inc. (NASDAQ: BIIB) by 36.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commissi
Thrivent Financial for Lutherans Raises Position in Biogen Inc. $BIIB
05:08am, Wednesday, 24'th Dec 2025
Thrivent Financial for Lutherans grew its position in shares of Biogen Inc. (NASDAQ: BIIB) by 24.2% during the second quarter, according to the company in its most recent disclosure with the Securitie
CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced that The Journal of the American Medical Association (JAMA) Neurology has published final results fro
Corient Private Wealth LLC Acquires 4,540 Shares of Biogen Inc. $BIIB
03:34am, Sunday, 21'st Dec 2025
Corient Private Wealth LLC boosted its holdings in shares of Biogen Inc. (NASDAQ: BIIB) by 15.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Com
Nasdaq-100 Shake-Up: These 6 Stocks Are In, 6 Are Out — And It Could Trigger Big Moves
06:01am, Monday, 15'th Dec 2025
The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, effective December 22, 2025.
Biogen Inc. $BIIB Shares Purchased by Balyasny Asset Management L.P.
03:52am, Saturday, 13'th Dec 2025
Balyasny Asset Management L.P. raised its holdings in shares of Biogen Inc. (NASDAQ: BIIB) by 5.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities
Biogen Inc. $BIIB Shares Sold by Daiwa Securities Group Inc.
04:14am, Friday, 12'th Dec 2025
Daiwa Securities Group Inc. lessened its holdings in Biogen Inc. (NASDAQ: BIIB) by 9.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The
Federated Hermes Inc. Acquires 17,069 Shares of Biogen Inc. $BIIB
04:20am, Thursday, 11'th Dec 2025
Federated Hermes Inc. raised its holdings in shares of Biogen Inc. (NASDAQ: BIIB) by 16.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission
Pre-Market Stock Futures: Futures are trading modestly lower as the big day has finally arrived: the Federal Reserve will wrap up its last meeting of 2025, and the odds still heavily favor a 25-basis-
TORONTO--(BUSINESS WIRE)--Biogen Canada Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) for ZURZUVAE™ (zuranolone) for the treatment of moderate or severe postpartum
TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Mas
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in sei
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's disease by up to 8.3 years in low-amyloid group who started tre
